Browsing: Therapeutics

Interested in Lineage Cell Therapeutics, Inc.? Here are five stocks we like better.

— First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome —

Relmada expects to file an IND for bladder cancer candidate NDV-01 by year-end 2026 and, if cleared, begin its Phase III SPECTRUM program with the first patient potentially enrolling in Q1 2027.

Ventures, the corporate venture capital platform of Crescent Enterprises, today announced its investment in Oyster Therapeutics, previously known as Kesmalea Therapeutics, as part of the company’s $60 million Series A financing. Oyster is a pharmaceutical company developing next-generation targeted protein degraders, with an initial focus on tau-driven neurodegenerative diseases such as Alzheimer’s

Janux Therapeutics reported third quarter 2026 results with a net loss of US$21.57 million and basic loss per share of US$0.34, and noted plans to share initial Phase 1 data for JANX011 in healthy volunteers after the period ended.

Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026

Emvena Therapeutics, a Philadelphia-based biotechnology company developing placenta-targeted messenger RNA medicines, has received the inaugural investment from the Penn-BioNTech Innovative Therapeutics Seed Fund. The financing will support development of Emvena’s investigational treatment platform for serious maternal and fetal conditions, beginning with preeclampsia.

(BUSINESS WIRE)–The Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund) today announced its investment in Emvena Therapeutics, a biotechnology company developing mRNA medicines designed to deliver treatments directly to the placenta to address serious maternal and fetal conditions. Emvena is the first company launched and financed by the PxB Fund, which supports the translation of promising…

This is a paid press release. Contact the press release distributor directly with any inquiries.

This is a paid press release. Contact the press release distributor directly with any inquiries.